Skip to main content
← All trials
Metastatic Malignant Neoplasm in the LiverCancerGut healthDrugPhase 2

What this study is

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

What's being tested

  • Capecitabine

    Intervention · DRUG

  • Temozolomide

    Intervention · DRUG

Both interventions

Given PO

Study details

Official title
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Sponsor
SWOG Cancer Research Network
Conditions
Metastatic Malignant Neoplasm in the Liver · Pancreatic Neuroendocrine Tumor · Stage I Pancreatic Neuroendocrine Tumor AJCC v8 · Stage II Pancreatic Neuroendocrine Tumor AJCC v8 · Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Enrolling
141 people
Starts
2022-05-05
Est. completion
2027-03-31
Design
Open-label, randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗